Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Experts are expecting strong results driven by the robust sales of Lilly's blockbuster medications, particularly the diabetes franchise. However, there are also concerns about potential challenges fro